Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DHAINASDAQ:NURONASDAQ:POAINYSEAMERICAN:VTAK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDHAIDIH Holding US$0.22-0.9%$0.21$0.12▼$3.67$10.46M0.02646,562 shs9.02 million shsNURONeuroMetrix$4.55+4.4%$4.50$2.66▼$4.73$9.37M1.8216,149 shs35,522 shsPOAIPredictive Oncology$0.87-3.3%$1.00$0.55▼$3.06$7.77M1.21.93 million shs119,781 shsVTAKCatheter Precision$0.30-8.0%$0.28$0.16▼$8.40$3.31M-0.854.45 million shs1.40 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDHAIDIH Holding US0.00%0.00%-5.39%-31.58%-93.30%NURONeuroMetrix0.00%0.00%0.00%+0.11%+22.64%POAIPredictive Oncology0.00%-9.38%-10.87%-22.32%-2.68%VTAKCatheter Precision0.00%-17.81%+25.05%-23.86%-95.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDHAIDIH Holding US0.2626 of 5 stars0.03.00.00.00.61.70.0NURONeuroMetrixN/AN/AN/AN/AN/AN/AN/AN/APOAIPredictive Oncology1.4899 of 5 stars3.03.00.00.00.00.00.6VTAKCatheter Precision0.3237 of 5 stars0.02.00.00.01.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDHAIDIH Holding US 0.00N/AN/AN/ANURONeuroMetrix 0.00N/AN/AN/APOAIPredictive Oncology 2.00Hold$3.00244.83% UpsideVTAKCatheter Precision 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDHAIDIH Holding US$64.47M0.16N/AN/A($0.80) per share-0.28NURONeuroMetrix$3.03M3.09N/AN/A$13.18 per share0.35POAIPredictive Oncology$1.62M4.80N/AN/A($0.03) per share-29.00VTAKCatheter Precision$420K7.87N/AN/A$1.33 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDHAIDIH Holding US-$8.44M-$0.30N/A∞N/A-13.59%N/A-25.97%N/ANURONeuroMetrix-$6.53M-$4.59N/A∞N/A-203.71%-42.56%-39.26%8/4/2025 (Estimated)POAIPredictive Oncology-$12.66M-$3.05N/AN/AN/A-629.68%-671.29%-132.49%8/12/2025 (Estimated)VTAKCatheter Precision-$16.64MN/A0.00N/AN/A-3,744.91%-153.90%-68.25%8/13/2025 (Estimated)Latest VTAK, POAI, NURO, and DHAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025POAIPredictive Oncology-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDHAIDIH Holding USN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/AVTAKCatheter PrecisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDHAIDIH Holding USN/A0.510.34NURONeuroMetrixN/A13.8812.70POAIPredictive OncologyN/A0.760.75VTAKCatheter PrecisionN/A0.210.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDHAIDIH Holding US27.76%NURONeuroMetrix19.40%POAIPredictive Oncology9.04%VTAKCatheter Precision20.34%Insider OwnershipCompanyInsider OwnershipDHAIDIH Holding US49.58%NURONeuroMetrix7.30%POAIPredictive Oncology3.44%VTAKCatheter Precision2.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDHAIDIH Holding USN/A47.34 million23.87 millionN/ANURONeuroMetrix202.06 million1.90 millionNot OptionablePOAIPredictive Oncology308.93 million8.63 millionNot OptionableVTAKCatheter Precision1411.02 million10.69 millionN/AVTAK, POAI, NURO, and DHAI HeadlinesRecent News About These CompaniesCatheter Precision, Inc. Addresses Increased Trading Activity in Common StockJune 12, 2025 | quiverquant.comCatheter Precision, Inc. Comments on Recent Market ActivityJune 12, 2025 | globenewswire.comCatheter Precision (VTAK) Reports Key Progress for the LockeT ProductJune 12, 2025 | finance.yahoo.comCatheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University HospitalJune 9, 2025 | finance.yahoo.comCatheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University Hospital | ...June 9, 2025 | gurufocus.comCatheter Precision, Inc. Secures First Order for VIVO Product from Sahlgrenska University Hospital in SwedenJune 9, 2025 | quiverquant.comCatheter Precision, Inc. Receives CE Mark Approval for LockeT, Expanding Market Opportunities in EuropeMay 27, 2025 | quiverquant.comCatheter Precision, Inc. Receives CE Mark for LockeTMay 27, 2025 | globenewswire.comCatheter Precision Enters Market Offering AgreementMay 19, 2025 | tipranks.comCatheter Precision, Inc. Announces First Quarter 2025 Update and Financial ResultsMay 15, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and ...May 12, 2025 | gurufocus.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic AllianceMay 12, 2025 | globenewswire.comCatheter Precision Finalizes Strategic Cardiac AcquisitionMay 8, 2025 | tipranks.comCatheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure AssetsMay 6, 2025 | finance.yahoo.comNew Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association ConferenceMay 1, 2025 | finance.yahoo.comCatheter Precision to Attend and Participate in the 46th Heart Rhythm SocietyApril 24, 2025 | finance.yahoo.comCatheter Precision Acquires Late-Stage Heart Failure Therapy AssetsApril 23, 2025 | theglobeandmail.comCatheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart FailureApril 23, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces Receipt of Audit Opinion with Going Concern DoubtApril 17, 2025 | quiverquant.comCatheter Precision Makes NYSE American Section 610(b) Public AnnouncementApril 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTAK, POAI, NURO, and DHAI Company DescriptionsDIH Holding US NASDAQ:DHAI$0.22 0.00 (-0.90%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.29 +0.07 (+31.22%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.NeuroMetrix NASDAQ:NURO$4.55 +0.19 (+4.36%) Closing price 05/1/2025Extended Trading$4.55 0.00 (0.00%) As of 05/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Predictive Oncology NASDAQ:POAI$0.87 -0.03 (-3.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.90 +0.03 (+2.87%) As of 06/20/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Catheter Precision NYSEAMERICAN:VTAK$0.30 -0.03 (-8.03%) Closing price 06/20/2025 04:10 PM EasternExtended Trading$0.30 -0.01 (-1.67%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company sells it products through distribution partners, independent sales agents, and direct employees. Catheter Precision, Inc. is based in Fort Mill, South Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
